Kiromic BioPharma, Inc. (NASDAQ:KRBP – Get Free Report) shares traded up 1.5% on Tuesday . The company traded as high as $2.64 and last traded at $2.64. 355 shares were traded during mid-day trading, a decline of 96% from the average session volume of 8,360 shares. The stock had previously closed at $2.60.
Kiromic BioPharma Trading Up 2.7 %
The stock’s 50 day moving average price is $2.67 and its 200 day moving average price is $1.44. The firm has a market cap of $3.50 million, a PE ratio of -0.18 and a beta of 2.00.
Kiromic BioPharma (NASDAQ:KRBP – Get Free Report) last issued its earnings results on Monday, March 18th. The company reported ($4.16) EPS for the quarter.
About Kiromic BioPharma
Kiromic BioPharma, Inc, an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company develops ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1.
Recommended Stories
- Five stocks we like better than Kiromic BioPharma
- Investing In Preferred Stock vs. Common Stock
- Hasbro’s Management Made All the Right Calls This Quarter
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- The 3 Best Fintech Stocks to Buy Now
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Kiromic BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiromic BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
